Emcure Competitors

Stocks . India . 
Stock . Emcure Pharmaceuticals
EMCURE Stock   1,373  16.15  1.16%   
Emcure Pharmaceuticals competes with Akums Drugs, Innova Captab, Kingfa Science, and Rico Auto; as well as few others. The company operates under Healthcare sector and is part of Drug Manufacturers - Specialty & Generic industry. Analyzing Emcure Pharmaceuticals competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Emcure Pharmaceuticals to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Emcure Pharmaceuticals Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Emcure Pharmaceuticals competition on your existing holdings.
  
Hype
Prediction
LowEstimatedHigh
1,3811,3831,525
Details
Intrinsic
Valuation
LowRealHigh
1,1631,1651,525
Details
Naive
Forecast
LowNextHigh
1,3671,3691,371
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
1,3451,3751,406
Details

Emcure Pharmaceuticals Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Emcure Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Emcure and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Emcure Pharmaceuticals does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
GATECHDVR
+ 0.82
RICOAUTO
TBZ
+ 0.78
EMCURE
RICOAUTO
+ 0.77
EMCURE
GATECHDVR
+ 0.77
KINGFA
AKUMS
+ 0.75
EMCURE
DELTAMAGNT
+ 0.75
COSMOFIRST
  
High negative correlations   
INNOVACAP
- 0.93
AKUMS
INNOVACAP
- 0.65
EMCURE
RICOAUTO
- 0.64
INNOVACAP
TBZ
- 0.58
INNOVACAP
DELTAMAGNT
- 0.58
AKUMS
COSMOFIRST
- 0.58
AKUMS

Risk-Adjusted Indicators

There is a big difference between Emcure Stock performing well and Emcure Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Emcure Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
EMCURE  1.58 (0.16) 0.00 (0.22) 0.00 
 0.00 
 3.60 
(4.02)
 11.60 
AKUMS  2.18 (0.56) 0.00 (0.83) 0.00 
 0.00 
 4.99 
(5.00)
 14.55 
INNOVACAP  2.50  0.33  0.12  1.05  2.35 
(2.99)
 5.03 
(3.97)
 16.62 
KINGFA  1.79  0.02  0.00  0.24  1.84 
(2.31)
 3.98 
(3.65)
 8.70 
RICOAUTO  1.72 (0.46) 0.00 (0.58) 0.00 
 0.00 
 3.21 
(4.52)
 9.85 
GATECHDVR  2.48 (0.32) 0.00  5.40  0.00 
 0.00 
 4.08 
(5.56)
 12.29 
COSMOFIRST  1.99  0.36  0.13 (1.63) 2.01 
(2.15)
 5.20 
(3.84)
 16.21 
DELTAMAGNT  2.41  0.22  0.08  0.21  2.33 
(2.89)
 7.69 
(4.49)
 19.73 
TBZ  2.78 (0.18) 0.00 (0.30) 0.00 
 0.00 
 6.65 
(5.61)
 17.64 
PARAGMILK  2.19  0.15  0.05  0.23  2.53 
(2.43)
 5.30 
(4.75)
 12.83 
All Fundamental Data

Emcure Pharmaceuticals Competitive Analysis

The better you understand Emcure Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Emcure Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Emcure Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
EMCURE AKUMS INNOVACAP KINGFA RICOAUTO GATECHDVR COSMOFIRST DELTAMAGNT TBZ PARAGMILK
 1.16 
 1,373 
Emcure
 2.18 
 572.80 
Akums
 3.79 
 978.55 
Innova
 3.71 
 3,419 
Kingfa
 2.90 
 85.16 
Rico
 1.03 
 0.98 
GACM
 3.33 
 954.05 
COSMO
 3.44 
 108.31 
Delta
 3.31 
 251.28 
Tribhovandas
 1.83 
 194.82 
Parag
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very steady
Very steady
Very steady
Dangerous
Very steady
Very steady
Very steady
Very steady
Market Performance
(90 Days Performance)
Very Weak
Very Weak
OK
Insignificant
Very Weak
Very Weak
OK
Insignificant
Very Weak
Insignificant
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Low
Very Low
Very Small
Below Average
Very High
Very Low
Below Average
Very Low
Very Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Under Valued
Over Valued
Over Valued
Over Valued
Over Valued
Fairly Valued
Fairly Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Cautious Hold
Sell
Buy
Strong Sell
Cautious Hold
Strong Sell
Strong Sell
Cautious Hold
Sell
Hold
Net Asset
N/A
N/A
13.21 B
9.94 B
18.95 B
123.46 M
35.28 B
951.58 M
14.59 B
18.91 B
Profit Margin
0.074
0.0578
0.1
0.0822
0.0174
0.19
0.0303
-0.13
0.0259
0.0312
EBITDA
12.05 B
4.96 B
1.67 B
1.87 B
2.31 B
N/A
2.5 B
(14.5 M)
1.42 B
2.23 B
Operating Margin
0.13
0.0884
0.14
0.12
0.0385
0.24
0.0632
-0.0911
0.059
0.0668
Current Valuation
295.8 B
134.21 B
58.36 B
41.37 B
18.42 B
925.02 M
32.13 B
1.56 B
22.9 B
29.54 B
Price To Book
9.39
18.53
6.25
6.34
1.6
12.43
1.74
5.64
2.71
2.41
Retained Earnings
N/A
N/A
3.25 B
3.15 B
4.36 B
(637.16 M)
12.21 B
(233.8 M)
3.67 B
(8.01 M)
Beta
N/A
N/A
N/A
0.98
1.0
0.21
0.6
0.41
1.06
0.78
Number Of Employees
N/A
7.39 K
N/A
257
2.4 K
5
1.24 K
378
997
1.77 K
Shares Outstanding
N/A
157.39 M
57.22 M
12.11 M
135.28 M
118.22 M
25.97 M
10.85 M
66.73 M
119.2 M
Cash Flow From Operations
N/A
N/A
1.46 B
161.02 M
2.47 B
3.55 M
2.45 B
16.08 M
396.89 M
991.13 M
Annual Yield
N/A
N/A
N/A
0.0035
0.007
N/A
0.0039
N/A
0.0072
0.0026
Total Debt
N/A
N/A
2.45 B
325.46 M
6.88 B
190.4 M
10.48 B
398.56 M
6.14 B
6.45 B
Return On Equity
N/A
N/A
0.18
0.23
0.0549
N/A
0.047
-0.32
0.0937
0.11
Book Value Per Share
162.97
49.59
156.53
538.95
52.75
0.18
513.34
24.75
90.14
80.72
Return On Asset
N/A
N/A
0.0759
0.11
0.0316
N/A
0.0176
-0.0358
0.0493
0.0574
Total Asset
N/A
N/A
13.21 B
9.94 B
18.95 B
123.46 M
35.28 B
951.58 M
14.59 B
18.91 B
Target Price
1575.0
N/A
N/A
37.0
N/A
N/A
N/A
N/A
120.0
260.0
Last Dividend Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.5
Shares Owned By Institutions
3.53
5.14
18.43
0.007
1.3
N/A
2.04
N/A
0.24
8.97
Market Capitalization
270.98 B
130.91 B
55 B
34.96 B
11.52 B
839.38 M
24.78 B
1.21 B
16.77 B
23.22 B
Price To Sales
3.92
3.09
4.76
2.54
0.53
12.69
0.95
1.46
0.72
0.72
Net Income
N/A
N/A
1.3 B
1.23 B
383.4 M
(11.77 M)
621.9 M
(103.71 M)
544.27 M
905.83 M
Earnings Per Share
26.38
0.08
22.9
110.82
2.85
0.03
39.31
-10.31
9.45
8.14
Shares Owned By Insiders
86.77
82.61
72.55
86.38
51.36
N/A
49.0
73.6
78.66
54.47
Revenue
69.17 B
42.31 B
10.77 B
14.87 B
21.6 B
103.86 M
25.87 B
835.74 M
22.99 B
31.39 B
Working Capital
N/A
N/A
N/A
3.23 B
(986.6 M)
29.7 M
2.18 B
(147.99 M)
5.11 B
6.04 B
Cash And Equivalents
N/A
N/A
N/A
N/A
N/A
N/A
N/A
5.26 M
375.76 M
137.99 M
Gross Profit
N/A
N/A
N/A
2.83 B
6.61 B
N/A
10.63 B
499.32 M
2.84 B
5.59 B
Day Typical Price
1367.63
571.68
991.23
3428.47
86.17
0.98
975.17
110.07
255.3
195.82
Accumulation Distribution
0.0289
0.0637
0.0567
0.0659
0.038
N/A
0.0699
0.0655
0.0581
0.0411
Market Facilitation Index
40.0
37.55
58.25
234.0
3.36
N/A
71.35
7.51
15.39
8.23
Daily Balance Of Power
(0.40)
0.3249
(0.66)
0.5222
(0.76)
9.2 T
(0.46)
(0.51)
(0.56)
(0.44)
Period Momentum Indicator
(16.15)
12.2
(38.60)
122.2
(2.54)
0.01
(32.90)
(3.86)
(8.60)
(3.63)
Rate Of Daily Change
0.99
1.02
0.96
1.04
0.97
1.01
0.97
0.97
0.97
0.98
Day Median Price
1365.0
571.13
997.58
3433.0
86.68
0.98
985.72
110.96
257.31
196.32
Price Action Indicator
(0.17)
7.77
(38.33)
47.5
(2.79)
0.005
(48.13)
(4.57)
(10.33)
(3.31)
Coefficient Of Variation
(1,686)
(572.91)
947.1
6088.8
(511.23)
(1,008)
812.91
1428.9
(2,385)
1639.59
Mean Deviation
1.58
2.18
2.5
1.79
1.72
2.48
1.99
2.41
2.78
2.19
Jensen Alpha
(0.16)
(0.56)
0.3298
0.0247
(0.46)
(0.32)
0.3593
0.2165
(0.18)
0.1502
Total Risk Alpha
(0.21)
(0.64)
0.2449
(0.04)
(0.50)
(0.41)
0.2715
0.1409
(0.27)
0.0852
Sortino Ratio
N/A
N/A
0.1189
0.0026
N/A
N/A
0.1344
0.0832
N/A
0.0526
Downside Variance
N/A
N/A
7.01
3.7
N/A
N/A
6.11
6.95
N/A
7.46
Standard Deviation
2.28
3.09
3.29
2.27
2.21
3.1
2.96
3.59
3.71
2.89
Kurtosis
1.46
1.54
1.51
0.296
0.0635
(0.74)
6.4
3.98
0.6731
0.3451
Potential Upside
3.6
4.99
5.03
3.98
3.21
4.08
5.2
7.69
6.65
5.3
Treynor Ratio
(0.22)
(0.83)
1.05
0.2387
(0.58)
5.4
(1.63)
0.2142
(0.30)
0.2332
Maximum Drawdown
11.6
14.55
16.62
8.7
9.85
12.29
16.21
19.73
17.64
12.83
Variance
5.19
9.56
10.79
5.13
4.88
9.64
8.78
12.92
13.76
8.33
Market Risk Adjusted Performance
(0.21)
(0.82)
1.06
0.2487
(0.57)
5.41
(1.62)
0.2242
(0.29)
0.2432
Risk Adjusted Performance
(0.04)
(0.13)
0.0912
0.0195
(0.15)
(0.07)
0.1048
0.0632
(0.03)
0.0556
Skewness
0.0844
(0.68)
0.9186
0.5962
(0.21)
(0.18)
1.63
1.63
0.5139
0.3438
Semi Deviation
N/A
N/A
2.35
1.84
N/A
N/A
2.01
2.33
N/A
2.53
Information Ratio
(0.07)
(0.18)
0.0958
0.0022
(0.21)
(0.11)
0.1122
0.061
(0.05)
0.0498
Value At Risk
(4.02)
(5.00)
(3.97)
(3.65)
(4.52)
(5.56)
(3.84)
(4.49)
(5.61)
(4.75)
Expected Short fall
N/A
N/A
(2.99)
(2.31)
N/A
N/A
(2.15)
(2.89)
N/A
(2.43)
Downside Deviation
N/A
N/A
2.65
1.92
N/A
N/A
2.47
2.64
N/A
2.73
Semi Variance
N/A
N/A
5.52
3.38
N/A
N/A
4.05
5.45
N/A
6.4

Emcure Pharmaceuticals Competition Performance Charts

Five steps to successful analysis of Emcure Pharmaceuticals Competition

Emcure Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Emcure Pharmaceuticals in relation to its competition. Emcure Pharmaceuticals' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Emcure Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Emcure Pharmaceuticals' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Emcure Pharmaceuticals, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Emcure Pharmaceuticals position

In addition to having Emcure Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Real Estate ETFs Thematic Idea Now

Real Estate ETFs
Real Estate ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Real Estate ETFs theme has 65 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Real Estate ETFs Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Emcure Stock

Emcure Pharmaceuticals financial ratios help investors to determine whether Emcure Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Emcure with respect to the benefits of owning Emcure Pharmaceuticals security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY